Stock Events

Stock Events

Skye Bioscience 

0
36
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7AugExpected
Q1 2026
Next
-0.27
-0.25
-0.23
-0.22
Expected EPS
-0.21634336472000001
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-48.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 09R0.STU. It's not an investment recommendation.
NVIDIA
8
NVDA
Microsoft
7
MSFT
Apple
6
AAPL
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Corbus Pharmaceuticals
CRBP
Mkt Cap179.35M
Corbus Pharmaceuticals works on developing and commercializing novel therapeutics to treat inflammatory and fibrotic diseases, overlapping with some of Skye Bioscience's therapeutic targets.
Aurora Cannabis
ACB
Mkt Cap167.86M
Aurora Cannabis is a major player in the cannabis industry, and while primarily focused on recreational and medicinal cannabis products, its interest in medical research could position it as a competitor in cannabinoid therapeutics.
Tilray Brands
TLRY
Mkt Cap545.68M
Tilray is engaged in pharmaceutical-grade cannabis research, cultivation, processing, and distribution, making it a competitor in the cannabinoid-based pharmaceuticals market.
Canopy Growth
CGC
Mkt Cap435.5M
Canopy Growth Corporation operates in the cannabis and hemp-based consumer product markets but also invests in research and development for cannabinoid-based medicines.
Curaleaf
CURLF
Mkt Cap2.5B
Curaleaf Holdings operates in the cannabis retail and medical cannabis markets, and its involvement in developing cannabis-based medicinal products makes it a competitor in the cannabinoid therapeutics field.

About

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Show more...
CEO
Mr. Punit S. Dhillon B.A.
Employees
12
Country
United States
ISIN
US83086J1016

Listings

MU
DE
09R0.MU
MU
DE
09R.MU
STU
DE
09R0.STU
XNAS
US
SKYE

0 Comments

Share your thoughts

FAQ

What is Skye Bioscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Skye Bioscience stocks are traded under the ticker 09R0.STU.
When is the next Skye Bioscience earnings date?▼
Skye Bioscience is going to release the next earnings report on August 07, 2026.
What were Skye Bioscience earnings last quarter?▼
09R0.STU earnings for the last quarter are -0.27 EUR per share, whereas the estimation was -0.26 EUR resulting in a -3.72% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Skye Bioscience revenue for the last year?▼
Skye Bioscience revenue for the last year amounts to 0 EUR.
What is Skye Bioscience net income for the last year?▼
09R0.STU net income for the last year is -48.39M EUR.
How many employees does Skye Bioscience have?▼
As of July 16, 2026, the company has 12 employees.
In which sector is Skye Bioscience located?▼
Skye Bioscience operates in the Health & Wellness sector.
When did Skye Bioscience complete a stock split?▼
Skye Bioscience has not had any recent stock splits.
Where is Skye Bioscience headquartered?▼
Skye Bioscience is headquartered in San Diego, United States.